March 29, 2018
Whom It May Concern
Company:KYORIN Holdings, Inc.
Representative: Minoru Hogawa
Representative Director, President(Security Code: 4569, TSE 1st Sec.)Contact:Shuji Miyaki,Director, Corporate Communication
Telephone:(0)3-3525-4707

Kyorin Pharmaceutical Sign a License Agreement for “SK-1404,”
a Therapeutic Agent for Nocturia Due to Nocturnal Polyuria

TOKYO, Japan – March 29, 2018 KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo; President
and CEO: Minoru Hogawa; “Kyorin Pharmaceutical”), a wholly owned subsidiary of KYORIN Holdings, Inc., andSanwa Kagaku Kenkyusho Co., Ltd. (Head office: Nagoya, Aichi; President and CEO: Katsumi Hata; “Sanwa Kagaku”),
a wholly-owned subsidiary of Suzuken Co., Ltd. (Head office: Nagoya, Aichi; President and CEO: Hiromi Miyata), havesigned a License Agreement for “SK-1404,” a novel therapeutic agent for the treatment of nocturia.
Under the terms of this agreement, Kyorin Pharmaceutical acquires the exclusive license in Japan and Asia (Hong Kong,Taiwan, and 10 member states of ASEAN) to develop and commercialize SK-1404, and in return will make an upfront
payment to Sanwa Kagaku along with milestone payments.
SK-1404, a therapeutic agent for the treatment of nocturia, is a vasopressin V2 receptor agonist, which promotes thereabsorption of water in the renal collecting ducts to reduce urinary output (antidiuresis) in the same manner as arginine
vasopressin, an endogenous antidiuretic hormone. The drug has excellent absorbability, quickly exerts an antidiuretic
effect after administration, and will be promptly eliminated from the body. SK-1404 is expected to be a novel drug fortreatment of nocturia due to nocturnal polyuria with excellent efficacy and safety.
Currently, the drug is under phase II clinical study by Sanwa Kagaku in Japan. Going forward, both companies will
promote development, early commercialization and market penetration in order to contribute to QOL improvement ofpatients suffering from nocturia by providing novel options.
Kyorin Pharmaceutical is promoting a franchised customer strategy to concentrate business resources in specific fields(areas of focus: respiratory, otolaryngology and urology diseases). Through this agreement, Kyorin Pharmaceutical will
extend its product lineup in urology to enhance its presence.
We will record the upfront payment to Sanwa Kagaku under the agreement as selling and general and administrative
expenses (research and development expenses) in this fiscal year (ending March 2018), the impact of which on its
consolidated financial results will be announced as appropriate.

[Reference][About Nocturia Due to Nocturnal Polyuria]
Nocturia refers to a symptom in individuals who have to wake after bedtime for urination, the most frequent symptom
associated with urination. Approximately 45 million men and women aged 40 years and over have symptoms of nocturia,
which is known to be a symptom with the highest daily difficulty as the frequency of urination increases with age. Whilenocturnal polyuria (increase in urine production at night), reduced bladder capacity and sleep disorders are cited as causesof nocturia, there is no drug recommended for nocturia due to nocturnal polyuria. Also, the symptoms may not improvewith an overactive bladder therapeutic agent.

[Overview of the Contracting Companies]
Company nameSanwa Kagaku Kenkyusho Co., Ltd.

Kyorin Pharmaceutical Co., Ltd.

Representative

President & CEO: Katsumi Hata

President & CEO: Minoru Hogawa

JPY 2,101.08 million

JPY 4,317.00 million

R&D, manufacturing and marketing ofpharmaceuticals, diagnostics products,
contract manufacturing of pharmaceuticals
35
Higashisotobori-cho,Higashi-ku,
Nagoya, Aichi 461-8631, Japan

Manufacturingandpharmaceuticals.

CapitalBusiness activities

Address

URL

http://www.skk-net.com

ofOchanomizu Sola City, 6, Kanda
Surugadai 4-Chome, Chiyoda-ku, Tokyo
101-8311, Japan
http://www.kyorin-pharm.co.jp<Contact>
Sanwa Kagaku Kenkyusho Co., Ltd.
CSR & Public Relations Group, Business Administration Department
TEL: (0)52-951-8130
KYORIN Holdings, Inc.
Corporate Communication, President Office
TEL: (0)3-3525-4707

marketing